In a recent head-to-head, phase III trial (DESTINY-Breast03), TDXd treatment resulted in a statistically significant improvement in median PFS compared with T-DM1 and had manageable toxicity in patients with HER2-positive, unresectable BC.19 This evidence concerns the gene ERBB2 and breast cancer.